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Microvascular dysfunction is believed to precede the development and contribute 
to the progression of obesity related diseases such as insulin resistance, hypertension, and 
coronary artery disease. Multiple studies have found impaired microvascular 
endothelium-dependent vasodilation occurs prior to the onset of disease in middle aged 
adults. In order to test the hypothesis that the cutaneous microvasculature of young obese 
(BMI>30kg/m
2
), but otherwise healthy, adults would exhibit impaired microvascular 
response, we recruited 12 obese and 12 lean (BMI<25 kg/m
2
) individuals. Each group 
was age-matched and consisted of 5 females and 7 males. Each participant was 
instrumented with two microdialysis probes inserted in the dermis of the non-dominant 
forearm for a wide dose range of infusions of either the endothelium-dependent 
vasodilator methacholine (MCh) or the endothelium-independent vasodilator sodium 
nitroprusside (SNP). Each microdialysis site was clamped at 33°C with a local heater and 
affixed with a laser Doppler flux (LDF) probe for determination of local red blood cell 








-50mM) were infused at a rate of 2 µl/min for 8 minutes 
per dose. Both sites finished with heating to 43°C and infusion of 50mM SNP to confirm 
site specific maximal vasodilation. Blood pressure was recorded in the last minute of 
each stage and the corresponding LDF was used to calculate cutaneous vascular 
conductance (CVC). Dose response curves for CVC at each dose, as well as maximal 
CVC were analyzed. MCh dose response showed a trend toward endothelium–dependent 
impairment in obese (p=0.06) and maximal absolute CVC at the MCh site was attenuated 
in obese versus lean (2.70 ± 0.73 vs 3.30 ± 0.81 LDF/mmHg, p=0.027). Endothelium-
independent vasodilation with SNP was impaired at the 4 highest doses of SNP (all 
P<0.006) and maximal CVC was attenuated in obese compared to lean (2.44 ± 0.74 vs 
3.31 ± 0.65 LDF/mmHg, p=0.004). These results support the hypothesis that 
microvascular function is impaired in young, healthy obese, individuals; however they 
suggest the impairment is partially endothelium-independent. 
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Chapter 1: Introduction 
Background  
Cardiovascular disease is the leading cause of morbidity and mortality in obese 
individuals, especially those with additional risk factors of hypertension, dyslipidemia, 
microalbuminuria or insulin resistance (Isomaa et al., 2001). The microcirculation has been 
used as a novel location to detect the initial insult of cardiovascular impairments. 
Impairments in microvascular endothelial function, including decreased nitric oxide (NO)-
dependent vasodilation, vessel structural remodeling, and decreased perfusion due to 
rarefaction, may precede the development of hypertension (Cohuet & Struijker-Boudier, 
2006; Levy, Ambrosio, Pries, & Struijker-Boudier, 2001), atherosclerosis (Davignon & 
Ganz, 2004; Landmesser, Hornig, & Drexler, 2004) and insulin resistance (Serné, de Jongh, 
Eringa, IJzerman, & Stehouwer, 2007). It has been well established that obesity (BMI>30 
kg/m
2
) is related to development of hypertension (Kannel, Brand, Skinner, Dawber, & 
McNamara, 1967; Stamler, Stamler, Riedlinger, Algera, & Roberts, 1978) and insulin 
resistance (Mokdad, Ford, Bowman, & et al., 2003).  Therefore, it is likely that obesity 
contributes to microvascular dysfunction, which then influences the development of 
obesity-related diseases such as type 2 diabetes mellitus and cardiovascular disease. 
Supporting this hypothesis, capillary recruitment and cutaneous blood flow response to the 
endothelium-dependent vasodilator acetylcholine (ACh) have been correlated with impaired 
insulin sensitivity (de Jongh, Serné, IJzerman, de Vries, & Stehouwer, 2004b; Serné et al., 
1999). Similarly, slowed response to hyperemia and decreased functional capillary density 
are associated with both insulinemia and BMI (Panazzolo et al., 2012).  
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The effect of obesity on endothelial function has been previously examined. 
Attenuations in  forearm blood flow response to  intra-arterial infusions of ACh  have been 
shown in some (Higashi et al., 2001; Sivitz, Wayson, Bayless, Sinkey, & Haynes, 2007; 
Van Guilder, Stauffer, Greiner, & DeSouza, 2008), but not all (Tack, Ong, Lutterman, & 
Smits, 1998) obese individuals compared to their lean counterparts. Cutaneous blood flow 
is attenuated during post occlusive reactive hyperemia in obese adults (Rossi et al., 2011) 
suggesting a potential impairment in NO-production or action, though the NO contribution 
of this test is debated (Wong, Wilkins, Holowatz, & Minson, 2003). Similarly, impairments 
in cutaneous blood flow responsiveness to ACh delivered via iontophoresis infusions are 
present in middle aged obese adults (de Jongh et al., 2004b). 
Much less is known about microvascular function in young obese individuals prior 
to the onset of obesity-related disease and the results of the few studies that have been 
performed are difficult to interpret due to the variety of techniques used to analyze 
microvascular function.  Lean and obese young adults have shown no difference in brachial 
blood flow response to intra-arterial infusions of ACh and endothelium-independent 
vasodilator sodium nitropusside (SNP) (Limberg et al 2013).  In contrast, obese young 
adults demonstrated a lower cutaneous blood flow response to ACh iontophoresis (Al-
Tahami, Bee, Ismail, & Rasool, 2011). These data have left the effect of excess body 
weight on vascular reactivity difficult to interpret and led us to examine another technique 
to answer the question. 
Statement of Purpose 
Investigation of the  cutaneous microcirculation has been  recognized as a suitable 
model for assessment of mechanisms underlying systemic vascular disease (Debbabi, 
Bonnin, Ducluzeau, Leftheriotis, & Levy, 2010; Holowatz & Kenney, 2011; Holowatz, 
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Thompson-Torgerson, & Kenney, 2008b) and with the simultaneous use of microdialysis 
we have the advantage of being able to systematically examine mechanisms of impairment 
at the microvascular level without having a systemic effect. Therefore, this study aims to be 
the first to utilize microdialysis to examine microvascular function in relatively young 
obese individuals without any concomitant disease. 
Confirmation of microvascular dysfunction occurring prior to the onset of obesity 
related disease would give support to the body of literature that impairments in 
microvascular function precede the development of insulin resistance and hypertension. 
Furthermore, future use of microdialysis may allow for identification of the mechanisms by 
which obesity impairs microvascular function. Knowledge of which may prove invaluable 
in the prevention or early treatment of obesity-related disease prior to the onset of 
symptoms.  
Hypothesis 
 The hypothesis of this study is that cutaneous microvascular function, more 
specifically endothelium dependent and/or independent vasodilation is impaired in young, 
healthy obese individuals when compared to their age-matched lean counterparts.   
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Chapter 2: Review of Literature 
With approximately one-third of the adult population of the United States classified 
as obese (BMI>30kg/m
2
), obesity and the health complications of excessive body weight 
are an important area of research.  Recently, microvascular function has been identified as a 
possible early link between disease states and development of further disease. The 
following review intends to focus on the health consequences of obesity, how 
microvascular dysfunction may contribute to further complications, and the mechanisms 
through which obesity might influence these impairments 
Obesity and Related Diseases 
The health impact of obesity is of the utmost concern to scientists and clinicians. 
Roughly two thirds of the United States’ adult population is overweight and one third is 
obese (Flegal, Carroll, Ogden, & Curtin, 2010). In addition, about 17% of children and 
adolescents under the age of 20 are also obese. While some suggest obesity rates are 
levelling off (Rokholm, Baker, & Sørensen, 2010), others contend that the number of 
Americans with a BMI over 30kg/m
2
 will continue to climb, albeit at a slower rate than we 
have seen in the 1980s and 1990s (Flegal et al., 2010). One estimate states that nearly 65 
million more Americans will be obese by the year 2030 (Wang, McPherson, Marsh, 
Gortmaker, & Brown, 2011). That number includes a projected 50% obesity rate for males 
over the age of 20. Large epidemiological studies have shown that obesity relates strongly 
to diabetes (Chan, Rimm, Colditz, Stampfer, & Willett, 1994; Colditz, Willett, Rotnitzky, & 
Manson, 1995). These studies showed that diabetic risk is elevated not only by current 
BMI, but also by BMI at the age of maturity and adult weight gain. Additionally, increased 
BMI is associated with increased cardiovascular risk factors such as increased blood 
pressure, impaired fasting glucose, and dyslipidemia (Lamon-Fava, Wilson, & Schaefer, 
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1996). Taken together, this data suggests the consequences of obesity are dire for both the 
individual and the healthcare system. Illustrating the latter point, obesity related diseases 
are estimated to have cost $147 billion in 2008 (Finkelstein, Trogdon, Cohen, & Dietz, 
2009) and are expected to increase regularly to the point where additional obesity related 
spending will reach $48-66 billion per year by 2030 (Wang et al., 2011). While obesity 
prevention efforts must continue, science must also continue to work to elucidate the 
mechanisms which link obesity to development of disease thereby allowing the possible 
development of therapeutic interventions that can counteract the elevated risks associated 
with obesity. 
Microvascular Assessment 
Impaired microvascular function is thought to precede the onset of hypertension 
(Levy et al., 2001), atherosclerosis (Al Suwaidi et al., 2000), and insulin resistance (Jonk et 
al., 2007; Serné et al., 2007). For this reason, research into the pathogenesis of 
microvascular dysfunction in various disease states, such as obesity, can provide insight 
into the mechanisms that lead to further disease. The microvasculature is the level of the 
vascular system that has the greatest effect on resistance and is the location of nutrient 
exchange. Therefore, any impairment in the microcirculation could potentially lead to 
increased resistance, and thus blood pressure, and/or impaired glucose uptake.  
Many early studies used venous occlusion plethysmography to measure forearm or 
leg blood flow after intra-arterial infusions of vasoactive substances; however, this 
technique requires medical supervision. More recently the use of laser Doppler flowmetry 
(LDF) has become popular to study the cutaneous circulation. The cutaneous circulation is 
studied because it is considered to be an excellent model for full body microvascular 
function due to its ease of accessibility (Holowatz, Thompson-Torgerson, & Kenney, 
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2008a). Microvascular function is assessed with LDF in response to many different stimuli 
including post-occlusive reactive hyperemia (PORH), systemic and local thermal reactivity, 
and iontophoresis of vasoactive substances across the skin via electrical charge, and 
microdialysis infusion directly into the dermal layer. Using PORH, thermal reactivity and 
iontophoresis have the advantage of being non-invasive. However, these techniques all have 
limitations. For instance, PORH has been shown to be independent of NO (Wong et al., 
2003). Additionally, thermal reactivity is a complex phenomenon and the contribution of 
NO and other vasodilatory stimuli are dependent upon temperature and rate of heating 
(Choi, Brunt, Fujii, & Minson, 2014; Minson, Berry, & Joyner, 2001). Limitations to 
iontophoresis include: the dose is indirectly estimated as time charge is applied x electrical 
current strength (Tesselaar & Sjöberg, 2011), the potential for non-specific effects of the 
current to induce vasodilation (Droog & Sjöberg, 2003; Grossmann et al., 1995), and the 
inverse relationship between skin electrical resistance and vasodilation (Ramsay, Ferrell, 
Greer, & Sattar, 2002). On the other hand, microdialysis allows for systematic study of 
mechanism due to the ability to directly infuse enzyme inhibitors or substrates. 
Disadvantages include the somewhat invasive nature (Cracowski, Minson, Salvat-Melis, & 
Halliwill, 2006) and the need to allow for trauma induced hyperemia to subside before 
measurements can be taken.   
Endothelium-Dependent Vasodilation 
The endothelium is the single layer of cells lining the lumen of blood vessels and 
has the ability to release vasoactive substances in response to various stimuli. Endothelial 
function is a key indicator of overall vascular health and dysfunction influences the 
development of coronary artery disease, peripheral artery disease and cerebrovascular 
disease (Beckman, Creager, & Libby, 2002). Depending upon the stimuli, the endothelium 
can release vasoconstrictor substances like endothelin-1 and angiotensin II or vasodilators 
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like nitric oxide (NO) and endothelium derived hyperpolarizing factors (EDHF). The 
endothelium can also release prostaglandins that signal vascular smooth muscle cells 
(VSMC) to vasoconstrict (via thromboxane) or vasodilate (via prostacyclin). In-vivo, ACh 
or shear stress will signal the production of NO by endothelial nitric oxide synthase 
(eNOS).  In turn, this NO release diffuses into the adjacent VSMC triggering a cascade 
beginning with guanylate cyclase (GC), then cyclic guanosine monophosphate (cGMP) and 
finally protein kinase G (PKG), which ultimately lowers cytosolic calcium and relaxes the 
smooth muscle. In addition to NO, prostaglandins signal the VSMC in a similar manner as 
NO and have been shown, via cyclooxygenase (COX) inhibition, to be a  contributor to 
endothelium dependent vasodilation in response to ACh, (Doyle, Duling, McGahren, & 
Dora, 1997; Durand et al., 2004; Holowatz, Thompson, Minson, & Kenney, 2005; Kellogg, 
Zhao, Coey, & Green, 2005).  
The effect of obesity on endothelium dependent vasodilation is contested. An early 
study showed no difference in forearm blood flow via plethysmography between lean and 
obese individuals who had intra-arterial infusions of Ach (Tack et al., 1998). However, 
another study with a similar protocol showed that obese individual with and without 
impaired fasting glucose and those with Type 2 diabetes all had impaired forearm blood 
flow response to infusions of ACh (Sivitz et al., 2007). In agreement with these results, 
another group examined forearm blood flow in obese versus lean subjects and found the 
obese individuals to have blunted responses to muscarinic agonists ACh  and MCh also to 
bradykinin, substance P, and isoproterenol, therefore endothelial-impairment is not a 
muscarinic receptor deficiency (Van Guilder et al., 2008). Further supporting that 
impairments in endothelial dependent vasodilation are not confined to responsiveness to 
ACh, a study examining forearm blood flow in young, sedentary lean, obese and metabolic 
syndrome subjects found that responsiveness to epoprostenol, a prostaglandin, was 
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impaired in obese and metabolic syndrome subjects compared to lean counterparts 
(Limberg et al., 2013). Interestingly, they did not demonstrate impairment in ACh 
responsiveness versus controls.  
Similar discrepancies exist in studies using PORH. One study found that obese 
individuals had increased skin blood flow at baseline compared to age matched controls yet 
they showed lower skin blood flow following PORH (Rossi et al., 2011). Skin blood flow 
responses were examined 12 months after bariatric surgery and subsequent weight loss and 
baseline blood flow was decreased to that of the lean controls while PORH responses were 
augmented to the level of the lean (Rossi et al., 2011). These results support the hypothesis 
that excessive adiposity impairs endothelium function, but it can be restored through weight 
loss. Confounding these results, however, is a study by Schlager et al. in morbidly obese 
teenagers in which the authors showed an increased skin blood flow response to PORH 
along with a slowed recovery time (Schlager et al., 2011). These authors speculated that 
these results infer an impaired myogenic vasoconstrictor response in obese children and 
adolescents. While these two populations are different, it is interesting that the researchers 
showed nearly opposite responses and each concluded microvascular dysfunction to be a 
key component. 
Multiple research groups have used iontophoresis to transdermally deliver 
vasoactive substances via an electric charge to the cutaneous microcirculation which they 
measure with laser Doppler flowmetry or more recently laser Doppler imaging. Commonly, 
ACh is used as the endothelium dependent stimulus. Impairments in cutaneous blood flow 
responsiveness to ACh infusions have been shown in obese individuals (Al-Tahami et al., 
2011; de Jongh et al., 2004b). However, obese individuals with insulin resistance or Type II 
diabetes were able to show improvements in flow mediated dilation but not in cutaneous 
blood flow responsiveness to iontophoretic administration of ACh after a 6 month exercise 
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and lifestyle intervention (Hamdy et al., 2003).  This result can be explained in a variety of 
ways. First, the authors hypothesized that their unexpected findings could be explained by 
an increased sensitivity in conduit arteries compared to the microcirculation. However, a 
more likely explanation is that iontophoresis is not an ideal method to deliver ACh and 
other vasoactive drugs to the cutaneous microcirculation. Limitations of iontophoresis 
include the inability to calculate the exact dose being delivered and the potential for non-
specific vasodilation (Tesselaar & Sjöberg, 2011) as well as the individual variability in 
electrical resistance of the skin, which has been shown to negatively correlate with skin 
blood flow response (Ramsay et al., 2002). It is entirely likely that these factors could 
contribute to or hide differences seen between subject groups and therefore results of 
studies utilizing iontophoresis should be viewed with caution. 
 Endothelial function must also take into account endothelium dependent 
vasoconstriction. As discussed previously, obese children and adolescents may have 
inadequate myogenic vasoconstrictor responses (Schlager et al., 2011), but endothelial 
dysfunction should be viewed as exhibiting excessive basal vasoconstriction. For instance, 
when overweight and obese subjects were given arterial infusions of the potent endothelium 
derived vasoconstrictor endothelin-1 (ET-1), they displayed a blunted vasoconstrictor 
response (Weil et al., 2011). Interestingly, when given an endothelin receptor blockade 
(BQ-123), the overweight and obese subjects had a vasodilatory response while blood flow 
was unaffected in lean subjects. This indicates that overweight and obese have either 
greater basal ET-1 production or increased sensitivity leading to increased vasoconstriction. 
Similar results were seen in overweight and obese hypertensives in comparison with lean 
hypertensives (Cardillo, Campia, Iantorno, & Panza, 2004). However, the latter study, 
Cardillo et al., showed no difference in BQ-123-induced vasodilation between non-
hypertensive overweight and obese subjects versus non-hypertensive lean subjects, 
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suggesting that increased ET-1 activity may not be inherent to obesity. Previously Ferri et 
al. had shown no difference in circulating ET-1 in obese normotensives and obese 
hypertensives, yet both obese groups have greater ET-1 versus lean normotensives (Ferri et 
al., 1995).  
 The discovery that insulin has nitric oxide-induced vasodilatory actions has made it 
clear that part of insulin’s effect on blood glucose is its ability to direct blood flow to tissues 
and can leave us speculating at potential mechanisms through which obesity leads to insulin 
resistance (Laakso, Edelman, Brechtel, & Baron, 1990; Steinberg, Brechtel, Johnson, 
Fineberg, & Baron, 1994). The direct action of insulin on cutaneous blood flow has been 
investigated using iontophoresis in obese and lean women, with the obese showing a 
complete attenuation of insulin-induced vasodilation (de Jongh, Serné, IJzerman, Jørstad, & 
Stehouwer, 2008). There is an inherent difference in the plasma milieu in obese individuals 
compared to lean counterparts, but the effect of obesity-related elevated plasma free fatty 
acids (FFA) on microvascular function has been investigated in obese and lean women (de 
Jongh, Serné, IJzerman, de Vries, & Stehouwer, 2004a). Lean women with artificially 
elevated free fatty acids (FFAs) showed impaired capillary recruitment and responsiveness 
to ACh at rest and during a hyperinsulinemic clamp, suggesting that FFAs play a role in 
impairment of microvascular function in obese individuals. In contrast, obese women with 
artificially lowered FFA experienced improved capillary recruitment at rest and during 
hyperinsulinemia, but did not see any gains in ACh-induced vasodilation in either state. 
Once again, this latter finding was based on iontophoresis of ACh and therefore may be of 
limited value.  
 Any impairment in endothelial function at the microvascular level may manifest 
later as insulin resistance and/or hypertension. Research has shown that obese individuals 
are more likely to have impaired endothelium dependent vasodilation or excessive 
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endothelial dependent vasoconstriction. Taken together, it is reasonable that insulin 
resistance and hypertension are connected to obesity via the endothelial function of the 
microvasculature. 
Endothelium-Independent Vasodilation 
 As mentioned previously, endothelium-independent vasodilation is a measure of the 
VSMC response to NO-donors. Any impairment can be either inactivation/destruction of 
NO prior smooth muscle signaling, or compromised signaling of the NO-guanylate cyclase-
cGMP-PKG cascade.  
Endothelium-independent dysfunction has been shown in a variety of disease states, 
such as rheumatoid arthritis, hypercholesterolemia, and heart disease. In a study of 
rheumatoid arthritis patients, forearm blood flow was decreased with intra-arterial SNP 
infusions and correlated with markers of inflammation (Yki-Järvinen, Bergholm, & 
Leirisalo-Repo, 2003). Hypercholesterolemics also show an attenuated forearm blood flow 
response to SNP (Creager et al., 1990). In chronic heart failure patients, those with 
attenuated SNP forearm blood flow responses had a higher rate of hospital admissions for 
worsening of their disease (Nakamura et al., 2001). Similarly, coronary artery disease 
patients showed a lower effect of sublingual nitroglycerin as measured by peripheral artery 
tonometry (Bonetti et al., 2004).  
Within the cutaneous circulation, as shown by LDF response to iontophoresis, SNP 
produces blunted vasodilation in older smokers compared to their age matched non-smokers 
(Pellaton, Kubli, Feihl, & Waeber, 2002). Interestingly, this impairment is not seen in 
younger smokers suggesting that it takes time to develop. Young Type 1 diabetics exhibit 
impaired endothelium-independent vasodilation in the cutaneous microvasculature (Khan, 
Elhadd, Greene, & Belch, 2000)  as do lean and obese, but not overweight, hypertensive 
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adolescents (Monostori et al., 2010). Healthy aging has shown a decreased maximal 
response to SNP (Minson et al., 2001).  
Endothelial dependent microvascular dysfunction has been fairly well established in 
obesity, but the question remains if there can also be endothelium independent mechanisms 
that cause impairments in microvascular function in obesity. Sivitz et al. showed a 
decreased forearm blood flow response to SNP in obese, impaired fasting glucose and type 
2 diabetics compared to insulin sensitive lean individuals (Sivitz et al., 2007). Contrasting 
that result, Weil et al. have shown no change in forearm blood flow in response to SNP in 
obese versus lean controls (Weil et al., 2011). Furthermore, with iontophoretic treatment of 
SNP, differences in responses between obese and lean are not seen (de Jongh et al., 2004a; 
de Jongh et al., 2004b). However, Al-Tahimi and colleagues had a trend approaching 
significance (p=0.053) showing impaired vasodilation in response to SNP iontophoresis in 
relatively young obese individuals (Al-Tahami et al., 2011). Another study indicated the 
potential for impaired endothelium independent vasodilation by examining the brachial 
artery blood flow response to sublingual nitroglycerin and showed an obesity related 
impairment, with the subjects with the highest degree of visceral fat having a 35% 
impairment in vasodilation (Christou et al., 2012). These results suggest the possibility that 
obesity may also affect the VSMC responsiveness to nitric oxide, independent of 
endothelial function, but the mechanisms have not been established. 
Oxidative stress: A potential mechanism 
The contention of this review is that microvascular impairments, particularly 
endothelial dependent vasodilation, are a consequence of obesity and lead to the 
development of insulin resistance and hypertension. The connection between obesity and 
microvascular dysfunction is likely to be multifactorial, however one possible link is 
oxidative stress seen in obesity. Thorough investigation of this and other potential causes of 
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obesity induced microvascular function may lead to development of new therapies to 
combat the progression from obesity to microvascular dysfunction and subsequent disease.  
Systemic oxidative stress is highly correlated with obesity independent of insulin 
resistance  with each 5kg/m
2
 increase in BMI equating to a nearly 10% increase in oxidative 
stress measured in the urine (Keaney et al., 2003). In agreement with that finding, urinary 
and plasma measures correlated strongly with BMI and waist circumference (Furukawa et 
al., 2004). Owing to these observations, the influence of increased adiposity on oxidative 
stress was studied in animal models. In obese, non-diabetic mice, elevated oxidative stress 
was apparent versus lean control mice (Furukawa et al., 2004). Furthermore, the increased 
plasma oxidative stress was traced to the white adipose tissue with no differences in lipid 
oxidation being shown in liver or muscle tissue. This increase in lipid oxidation by the 
accumulated adipose tissue was linked to increased expression of NADPH-oxidase mRNA, 
decreased expression and activity of anti-oxidant enzyme mRNA and increased reactive 
oxygen species production by adipocytes. Though this is an animal model, similar 
consequences of excess adiposity can be assumed in humans. 
NADPH-oxidase is a likely link between obesity and endothelial dysfunction as 
seen in obesity. NADPH-oxidase reduces nitric oxide bioavailability by increasing 
production of the free radical superoxide (Landmesser, Harrison, & Drexler, 2006). 
Superoxide and nitric oxide then quickly react to form perioxynitrite before nitric oxide has 
a chance to exert its effect on the VSMC thus limiting its bioavailability and subsequent 
vasodilation (Kojda & Harrison, 1999). If endothelial nitric oxide synthase (eNOS) 
becomes uncoupled, either due to lack of substrate L-arginine or cofactor 
tetrahydrobiopterin (BH4), then it will produce superoxide rather than nitric oxide and 
further inhibit vasodilation. Whether obesity results in decreased L-arginine or BH4 is 
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currently unknown, but it stands to reason that some form of oxidative stress contributes to 
impaired endothelial dependent vasodilation in obesity. 
The pathways that affect microvascular function have been studied recently in other 
conditions also known to increase risk of insulin resistance and/or cardiovascular disease. 
For instance, a study in middle aged adults utilizing laser Doppler flowmetry in 
combination with local infusions of various NOS inhibitors via microdialysis showed that 
eNOS activity determines cutaneous vasodilatory responsiveness to local heating and ACh 
infusion (Bruning et al., 2012). This same group then determined that, in aged humans, oral 
BH4 supplementation increases cutaneous vascular conductance and that increase is entirely 
due to improved nitric oxide bioavailability (Stanhewicz, Bruning, Smith, Kenney, & 
Holowatz, 2012). Taken together, these results indicate the importance of nitric oxide 
production in vasodilation of an elevated risk population. Additionally, another at-risk 
group, young smokers, was studied using a single bolus of ACh administered via 
microdialysis (Fujii, Reinke, Brunt, & Minson, 2013). They found that smokers did see a 
significantly blunted increase in cutaneous vascular conductance compared to non-smokers, 
but this eNOS inhibition did not further attenuate the increase in vasodilation in response to 
a one-minute infusion of ACh, indicating that in young cigarette smokers, eNOS is 
significantly inhibited likely due to the elevated superoxide production known to occur in 
cigarette smoking. Lastly, chronic kidney disease is known to cause elevated oxidative 
stress and thus can be seen as a good model of the effect of oxidative stress on the 
cutaneous microvasculature (DuPont, Farquhar, Townsend, & Edwards, 2011). In a study 
of patients with stage 3 and 4 chronic kidney disease compared with aged matched controls, 
it was observed that the increase in cutaneous vascular conductance seen with local heating 
was attenuated in the patients and this impairment was due to the nitric oxide contribution.  
Local microdialysis infusions of the antioxidant ascorbic acid and the eNOS substrate L-
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arginine both restored microvascular function to the level of healthy controls. These results 
further support the role of oxidative stress as a cause of microvascular dysfunction in 
obesity. 
Perspectives 
Microvascular dysfunction is thought to be a possible link between obesity, insulin 
resistance and hypertension. Multiple studies support the idea that microvascular function is 
impaired in populations with increased risk of insulin resistance, hypertension, and 
cardiovascular disease. Additionally, multiple studies have demonstrated microvascular 
dysfunction in obese individuals.  However, it is important that this microvascular 
dysfunction is demonstrated in young obese individuals without signs of further disease in 
order to verify that impaired microvascular function precedes the development of obesity 
related disease. Preliminary work in our lab shows impaired endothelium dependent 
vasodilation in obese college aged individuals. Future research should focus on the 
mechanisms through which obesity impairs microvascular function, namely increased 
oxidative stress. While obesity prevention should be the utmost priority, appropriate 
therapeutic interventions for obese individuals that address endothelial function have the 
potential to lessen the rates of obesity related diseases such as insulin resistance and 
hypertension and could possibly ameliorate type II diabetes mellitus and cardiovascular 
disease in obese individuals. 
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Chapter 3: Methods 
Subjects and Ethical approval  
Twenty-four normotensive, non-smoking volunteers participated in this study. Of 
the 24 subjects, 12 were classified as obese (5 women, 7 men) with a body mass index 
(BMI) ≥ 30 kg/m
2
. The other 12 subjects (5 women, 7 men) were classified as lean with a 
BMI ≤ 25 kg/m
2 
and were recruited after the obese subjects in order to match age and 
gender. Participant characteristics are presented in Table 1. All subjects were free of 
diagnosed cardiovascular, metabolic or neurological disease. Smokers and individuals on 
prescription medication, including hormonal birth control, were excluded from the study. 
Women were tested in the early follicular phase of the menstrual cycle (days 2-7). Subjects 
were asked to avoid alcohol, strenuous exercise, and over-the-counter medications for 24 
hours prior to testing. All experimental procedures were approved by the Institutional 
Review Board of the University of Texas at Austin. All purposes, risks, and procedures of 
the study were explained to subjects and subjects gave written informed consent prior to 
participation. 
Instrumentation and Measurements 
Volunteers reported to the lab in the morning after fasting for 12 hours. Upon arrival 
to the lab, subjects were weighed to the nearest tenth of a kilogram and measured to the 
nearest half centimeter on a digital medical scale with platform stadiometer wearing light 
clothing (Seca 763, Seca, Chino, CA). Subjects were then positioned on a semi-recumbent 
patient bed and remained still for the remainder of the study. Blood pressure and heart rate 
were monitored with an electrosphygmomanometer with integrated ECG (Tango+, 
SunTech Medical, Raleigh, NC). The blood pressure cuff was placed on the dominant arm 
for auscultation of the brachial artery. All testing occurred in an air conditioned laboratory 
set to 22°C. 
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Two microdialysis fibers (CMA 31, CMA Microdialysis, Kista, Sweden) were inserted 
intradermally in the dorsal side of the non-dominant forearm as described previously 
(Minson et al., 2001). Briefly, a 25 gauge needle was inserted intradermally with entry and 
exit points approximately 2.5 cm apart. The microdialysis fiber was threaded through the 
lumen of the needle with the 1 cm semi-permeable membrane placed within the needle. The 
needle was then withdrawn leaving the membrane in the dermis and the microdialysis fiber 
was taped in place. The second site was located a minimum of 5 cm away. Both 
microdialysis fibers were then perfused with lactated Ringer’s solution for 60-90 minutes 
allowing for resolution of the hyperemic response to the needle-induced trauma. Infusion 
rate was controlled via a dual syringe pump set to 0.2 µl·min
-1
 (Pump 11 Plus, Harvard 
Apparatus, Holliston, MA).  
Blood analysis for fasting glucose and blood lipids was completed using fingertip 
blood samples in Cholestech LDX system (Alere, Waltham MA). Glycosylated hemoglobin 
content (HbA1C) was also measured with a fingertip blood sample (in2it II, Bio-Rad 
Laboratories, Hercules, CA). 
Experimental Protocol 
Red blood cell flux was measured via laser Doppler flowmeter (LDF) probes 
(VP2T, Moor Instruments, Wilmington, DE) placed immediately above each microdialysis 
site and connected to LDF monitor (moorVMS-LDF, Moor Instruments, Wilmington, DE). 
Each probe was inserted into a local heating element (PF450, Perimed AB, Stockholm, 
Sweden) that was securely taped to the skin. Local heaters (Periflux 5000, Perimed AB, 
Stockholm, Sweden) were set at 33° C to normalize skin temperature among participants at 
baseline.  
Endothelium dependent and endothelium independent vasodilation was assessed by  
response to seven doses of methacholine (MCh) (Acetyl-β-methylcholine chloride, Sigma-
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Aldrich, St. Louis, MO) and  sodium nitroprusside (SNP) (Nitropress, Sigma-Aldrich, St. 
Louis, MO), respectively. The microdialysis site for each drug was randomly assigned. 




mM while SNP doses ranged 
were similarly diluted from 5 x10
-5
 to 50 mM. Following a 10 minute baseline period, each 
dose of MCh and SNP was infused for ~8 minutes at 0.2 µl·min
-1
 beginning with the lowest 
dose. During the first minute of each dose, the infusion rate was set at 5.2 µl·min
-1
 to flush 
the microdialysis probe of the previous dose. The final dose of each drug was infused for 20 
minutes in order to establish a plateau in LDF response. Each site then was heated to 43°C 
and infused with 50 mM SNP to insure site specific maximal vasodilation had been 
reached. 
Data Analysis and Statistics 
LDF (in flux units) and skin temperature data were integrated with a data acquisition 
system (MP150, BIOPAC Systems, Goleta, CA) and recorded on a laboratory computer for 
off-line analysis (Acknowledge, BIOPAC, Goleta, CA). Blood pressure measurements were 
taken in the last minute of each infusion stage. The LDF at each site was averaged over the 
final minute of each stage and used to calculate cutaneous vascular conductance (CVC) 
which is defined as LDF/MAP) and expressed in arbitrary units (mV·mmHg
-1
). A dose 
response curve for each site was constructed using the CVC calculated at each dose. 
Statistical analysis software (SigmaPlot12.5, SyStat Software, San Jose, CA) was used to fit 
individual responses four parameter logistic curves for identification of the dose that 
elicited one-half of the maximal response (EC50) for each subject at each infusion site.  
Group mean EC50 for MCH and SNP were then compared with independent samples t-tests. 
CVC values for each dose were analyzed across groups via a two-way repeated measures 
ANOVA with dose as the repeated factor. Where appropriate, post hoc analyses were 
performed using Tukey’s HSD. Additionally maximal CVC response at each site was 
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identified, independent of dose, and evaluated with a one-tail independent samples t-test 
with the hypothesis that the obese group would have an impaired response. All descriptive 
characteristics were evaluated with two-tail tests, except where directional differences were 
part of the study design, i.e. weight and BMI. Differences were considered significant at the 
α level of 0.05.  All data are presented as mean ± standard deviation (SD). 
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Chapter 4: Results 
Subjects 
As shown in Table 1, subjects were well matched in age, height, sex and blood 
pressure. By design, the obese group had a greater weight and body mass index(BMI) 
versus the lean group (95.4 ± 13.1 vs 66.1 ± 11.8 kg, P<0.001; 33.5 ± 3.4 vs 22.3 ± 1.9 
kg/m
2
, P<0.001). Additionally, the obese group had lower HDL (32 ± 13 vs 54 ± 11mg/dl, 
P<0.001) and a higher LDL/HDL ratio (3.9 ± 2.0 vs 1.7 ± 0.8, P<0.001).  Though no 
differences in blood glucose concentration after an overnight fast were seen between groups 
(81 ± 11 vs 82 ± 10 mg/dl, P=0.75), obese did exhibit slightly higher HBA1c  (5 ± 0.6 vs 
4.5 ± 0.4%, P=0.04). 
Endothelium-Dependent Vasodilation 
Sensitivity to MCH was assessed by comparing calculated EC50 values as seen in 
Figure 1. Obese did not differ from lean (-3.60 ± 1.06 vs -3.60 ± 1.53 log-molar [MCH], 
P=0.99). However, as seen in Figure 2, there was a trend toward attenuated CVC in obese 
across the dose response curve with a main effect of group (P=0.06). Baseline CVC  at the 
MCH site was 0.29 ± 0.17 mV·mmHg
-1 
for Obese and 0.40 ± 0.19 mV·mmHg
-1 
for lean and 
was not different between groups (P=0.149). Figure 3 shows that maximum CVC at the 
MCH site was lower in obese (2.70 ± 0.73 vs 3.34 ± 0.81 mV·mmHg
-1
, p=0.027). Maximal 
CVC with MCh infusion, however, did not signifcantly correlate to BMI, as seen in Figure 
4. 
Endothelium-Independent Vasodilation 
Three subjects were not included in the SNP analysis due to technical problems with 
the microdialyisis membrane at this site. For the following data obese consists of 6 males/4 
females and lean consists of 6 males and 5 females.  As seen in Figure 5, SNP EC50 was not 
different between Obese  (-3.05 ± 0.61 log-molar [SNP]) and Lean (-3.66 ± 1.43 log-molar 
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[SNP]) (P=0.198).  Figure 6 shows an interaction effect of group x dose response to SNP 
(p=0.007) with attenuations in obese CVC at doses ranging from 0.05mM to 50mM (all 
P<0.006). Baseline CVC was not different at the SNP site between obese and lean groups 
(0.33 ± 0.21 vs 0.42 ± 0.14 mV·mmHg
-1
, P=0.237). Maximal CVC at the SNP site was 
attenuated in the obese (2.44 ± 0.74 vs 3.31 ± 0.65 mV·mmHg
-1
, p=0.005). Further 
supporting this attenuation in endothelium independent vasodilation amongst obese, each 
site was heated to 43°C and infused with 50mM SNP. Maximal CVC is attenuated in obese 
at both the MCh and SNPsites as seen in Figures 7 and 8, respectively. Maximal SNP-
induced CVC is negatively correlated with BMI (P=0.007), as seen in Figure 10.  
Within-Subject Comparisons 
As seen in Table 2, there were no differences in baseline or maximal CVC within 
groups. These results allow for the comparison of absolute, rather than relative, CVC 








Table 1: Subject Characteristics 
  Lean Obese P 
Sex M, F 7, 5 7, 5   
Age 24.6 ± 4.8 24.6 ± 4.9 0.87 
Height (cm) 171.6 ± 11 167.5 ± 8 0.27 
Weight (kg) 66.1 ± 11.8 95.4 ± 13.1* <0.001 
BMI (kg·m
-2
) 22.3 ± 1.9 33.7 ± 3.4* <0.001 
Systolic BP (mmHg) 113 ± 11 115 ± 9 0.63 
Diastolic BP (mmHg) 68 ± 8 66 ± 9 0.57 
Total Cholesterol (mg·dl
-1
) 157 ± 36 165 ± 42 0.60 
HDL (mg·dl
-1
) 54 ± 11 33 ± 13* <0.001 
LDL (mg·dl
-1
) 88 ± 29 106 ± 40 0.20 
LDL/HDL ratio 1.7 ± 0.8 3.9 ± 2* <0.001 
Triglycerides (mg·dl
-1
) 78 ± 43 135 ± 119 0.14 
Fasting Glucose (mg·dl
-1
) 82 ± 10 81 ± 11 0.75 
HbA1C (%) 4.5 ± 0.4 5 ± 0.6* 0.04 
 
Values are mean ± SD. M, Male; F, Female; BMI, body mass index; BP, Blood Pressure; 
HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1C, glycated 









Table 2: Maximal CVC within subjects comparison between MCH and SNP sites 
  Lean Obese Pooled 
Max CVC- MCh  3.46 ± 0.67 2.84 ± 0.64 3.17 ± 0.73 
Max CVC -SNP  3.31 ± 0.62 2.44 ± 0.70  2.90 ± 0.79 
P  0.6 0.22 0.27 
 
Values are mean ±  SD. Maximal CVC in mV·mmHg
-1
 for both MCh and SNP are 
compared within groups and pooled together. Comparisons are made within groups and as 
pooled data and are assessed with two tail dependent samples t-tests. Subjects who were not 
used in SNP analysis are not included in this analysis, therefore obese n=10 and lean n=11. 









Figure 1: Mean ± SD EC
50
 for MCh in lean and obese as determined by MCh dose response 




























Figure 2: CVC graph of MCh dose response curve. There is a trend toward a main effect of 





































Figure 3: Mean ± SD Maximal CVC response to MCh. There is a significant difference 


































Figure 4: Relationship of maximal MCh  CVC values to  BMI. There is a not a significant 

































Figure 5: Mean ± SD EC
50
 for SNP in lean and obese as determined by SNP dose response 































Figure 6: CVC graph of SNP dose response curve. There is a group x dose interaction 






































Figure 7: Mean ± SD Maximal CVC response to SNP. There is a significant attenuation in 


































Figure 8: Mean ± SD CVC response to 50mM SNP +43° at  MCh site. Obese has a 

































Figure 9: Mean± SD CVC response to 50mM SNP +43° at SNP site. Obese has a 




































Figure 10: Relationship of maximal SNP CVC values to  BMI. There is a significant 
negative correlation between SNP induced maximal CVC and BMI (P=0.007) 
  




























Chapter 5: Discussion 
To the best of our knowledge, this is the first study investigating microvascular 
function in young, otherwise healthy obese adults using the microdialysis technique. Our 
results suggest that young obese individuals exhibit an attenuated cutaneous microvascular 
vasodilation in response to pharmacological stimuli. Decreased endothelium-independent 
vasodilation has been correlated with increasing BMI in the macrocirculation (Christou et 
al., 2012) as well as the microvasculature (Khan et al., 2003). Additionally, SNP-induced 
increases in forearm blood flow has been shown to be attenuated in obese subjects (Sivitz et 
al., 2007)  
Impaired microvascular function is thought to precede the onset of hypertension 
(Levy et al., 2001; Noon et al., 1997), atherosclerosis (Al Suwaidi et al., 2000), and insulin 
resistance (Jonk et al., 2007; Serné et al., 2007). Additionally, the presence of 
microvascular dysfunction can worsen the prognosis for cardiovascular disease (Nakamura 
et al., 2001; Quyyumi, 2003). Since obesity is associated with these conditions, 
microvascular dysfunction is likely a contributing link between obesity and their 
development. This hypothesis is supported by the results of the current study suggesting 
that microvascular dysfunction occurs in young, at-risk individuals prior to the onset of 
diagnosable disease (Irving et al., 2002).  Impairment at the level of the microvasculature 
can cause decreased perfusion and increased pressure, resulting in less surface area for 
glucose uptake and elevated blood pressure, as well as rarefaction, which only exacerbates 
these issues (Jonk et al., 2007). 
Previous studies using iontophoresis to deliver pharmacological stimuli to the 
cutaneous microvascular have shown attenuations in vasodilatory response to endothelium-
dependent stimuli such as ACh while showing no difference in endothelium-independent 
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vasodilation via SNP in obese versus their age-matched lean counterparts (de Jongh et al., 
2004a; de Jongh et al., 2004b). However, caution must be taken when trying to interpret our 
results in light of these previous studies. These studies have mostly been performed on 
populations older than that of the current study and age itself has been known to effect 
microvascular function. The technique of iontophoresis involves the use an electrical charge 
for the infusion of substances across the skin and into the intradermal space. Non-specific 
effects of the electrical charge and individual difference in skin electrical resistance have 
been suggested and it is not possible to quantify the dose the dose that is actually being 
delivered intradermally (Droog & Sjöberg, 2003; Grossmann et al., 1995; Ramsay et al., 
2002). Supporting the potential limitation to iontophoresis, severely obese adolescents have 
been shown to exhibit impaired brachial and cutaneous dilation to exogenous nitrate, yet no 
difference after SNP iontophoresis (Montero et al., 2014). 
The results of the current study show attenuated endothelium-independent 
vasodilation across to multiple doses of SNP and an attenuated maximal endothelium 
dependent vasodilation in response to MCh. The impaired maximal response to MCh is 
difficult to interpret in the presence of attenuated response to SNP. SNP donates NO 
directly the VSMC to cause vasodilation; therefore our results indicate either an impaired 
response to NO at the VSMC or the degradation of NO prior to the relaxation of the VSMC. 
Either of these possible mechanisms would have an effect on the endothelium dependent 
response to vasodilation, since VSMC response to endothelial derived vasodilators is part of 
the process. Therefore, we cannot conclusively state that the endothelium is impaired in 
young, obese individuals. Any impairment in response to MCh could be attributed to 
impaired VSMC. Muscarinic stimulation of endothelium signals vasodilation of the VSMC 
with redundant mechanisms including NO, prostaglandins, and endothelial derived 
hyperpolarizing factor (EDHF) (Holowatz et al., 2005; Kellogg et al., 2005). Therefore, it is 
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possible that obesity could result in a greater impairment that is partially compensated and 
is thus not detectable without more mechanistic studies.  
Oxidative stress, namely superoxide, limits endothelial-mediated dilation by 
reacting with NO before it can signal SG in the VSMC. Oxidative stress has been 
implicated in the microvascular impairment present in many at-risk population including: 
hypertension (Holowatz & Kenney, 2007), chronic kidney disease (DuPont et al., 2011),  
healthy aging (Holowatz, Thompson, & Kenney, 2006), and cigarette smoking (Fujii, 
Brunt, & Minson, 2014). These studies demonstrated augmented endothelial-dependent 
response after local infusion of anti-oxidants such as ascorbic acid or Tempol. In rats, 
obesity relates to elevated levels of superoxide and impaired microvascular response to both 
ACh and SNP (Frisbee & Stepp, 2001). When treated with anti-oxidants, obese, but not 
lean, rats show augmentation of both endothelium-dependent and independent vasodilation. 
Russo et al. found that the VSMC of an obese rat artery has a higher level of cGMP in the 
basal state, but cGMP levels do not rise to the same degree as seen in lean rats when 
exposed to NO. Anti-oxidant treatment decreased cGMP levels and partially restored the 
vascular relaxation occurring after a NO-donor in-vitro (Russo et al., 2008). In light of these 
studies, it is likely that oxidative stress is a factor in the microvascular responses seen in the 
current study. 
However, other mechanisms may also contribute to the impaired response. Obesity 
is associated with increased plasma levels of the vasoconstrictor endothelin-1 (ET-1) (Ferri 
et al., 1995). ET receptor blockade produces vasodilation in obese that is not present in lean 
(Mather, Mirzamohammadi, Lteif, Steinberg, & Baron, 2002; Weil et al., 2011). Mather et 
al. then showed that ET receptor blockade increased NO availability suggesting that ET-1 
acts through both elevated constriction and impaired NO-mediated dilation (Mather, Lteif, 
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Steinberg, & Baron, 2004). Future research should examine the role of ET-1 in young, 
apparently healthy obese individuals.  
Commonly, microdialysis studies present results in terms of %CVCmax, where the 
CVC during any treatment is indexed to that specific site’s maximal CVC. This relative 
method allows for comparison of multiple sites within the same person while accounting for  
any variablity in cutaneous blood flow across the forearm. Therefore, within one person, the 
effect of various enzmatic inhibitors or substrates can be accurately compared. In the 
present study, we chose to compare groups in terms of absolute CVC for a given treatment 
since we were comparing across groups and not treatments within subjects. As seen in 
Table 2, the baseline and maximal CVC did not differ between MCh and SNP sites within 
either the obese or lean group. Lastly, with similar EC50 values between groups, similar 
relative CVC dose response curves would be expected, as our data shows, suggesting 
similar sensitivity, but not necessarily response, to SNP and MCh between Obese and Lean. 
Taken together these data support  the use of  absolute, rather than relative, CVC for 
comparison across groups. 
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Chapter 6: Limitations 
The current study has multiple limitations. A major limitiation of this study was the 
small sample size. The analysis at the MCh site included 12 subjects in each group while 
the SNP site only consisted of 11 lean and 10 obese subjects. This small sample size limits 
our ability to generalize our findings to a larger population and thus warrants further study. 
Additionally, the cutaneous microvasculature is considered a surrogate for whole body 
microvascular function, but may not reflect the functionality of other vascular beds. 
Furthermore, some may argue that the obese group could have received a lower effective 
dose of both MCh and SNP because they have a greater amount of tissue. However, we 
believe this not to be the case because the LDF probes were positioned immediately over 
the microdialysis membranes and microdialysis drug delivery is a local, not systemic, 
technique. The membranes were all inserted by the same investigator just below the surface 
of the skin, effectively standardizing the diffusion distance between obese and lean groups. 
 The use of  only two microdialysis sites, each of which infusing separate 
pharmacolic stimuli, limits the conclusions that can be drawn from our data. Using multiple 
sites with the same stimulus, such as heat or MCh, while also administering blockers 
(eNOS, ET-1, or arginase inhibitors) or supplements (ascorbate, L-arginine, BH4) and 
comparing responses both within individuals and across groups allows for a more thorough 
assessment of what pathways are being effected by obesity. Future studies should take a 
more mechanistic approach.  
While subjects were instructed to avoid medications for 24 hours prior to testing, it 
has been shown that aspirin can impair endothelium-dependent vasodilation for at least 
three days via a decreased prostaglandin production (Durand et al., 2004). Though it is 
unlikely our obese group happened to consume COX-inhibitor drugs in the days prior to 
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testing at a higher rate than the lean group, future studies should prohibit medications for a 
week prior to testing.  
Another limitation to our study is that we did not measure insulin sensitivity, waist 
circumference or total body fat, which have all been shown to correlate to microvascular 
dysfunction. Without these measurements, it is possible that this study did not include 
enough subjects of the central-obesity phenotype. Additionally, length of obesity should be 
assessed in regards to the development of microvascular dysfunction. Finally, our study 
only used a rough index of self-reported physical activity, so we are unable to determine if 
any group differences may just be related to differences in activity or fitness level between 
groups. Physical fitness has been shown to augment endothelium dependent vasodilation   
(Black, Green, & Cable, 2008; Pugh et al., 2013; Wang, 2005). Other studies have shown 
improved response to incremental heating, but no change in maximal response to SNP, after 
an exercise training program. Therefore it may not be likely that different activity levels in 
the current study would change the results, but future studies need to include accurate 
physical activity measures in order to avoid this limitation. 
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Chapter 7: Conclusions 
 To the best of our knowledge our study is the first to examine the cutaneous 
microvasculature in healthy young obese individuals using a microdialysis technique. Our 
major finding implicated the endothelium-independent impairments in this apparently 
disease-free population. Though the precise mechanism of the attenuated response to SNP 
warrants further study, previous research in animals suggests a role for elevated oxidative 
stress. Future research needs to elucidate the mechanisms contributing to the observed 
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Introduction 
The purpose of this form is to provide you information that may affect your decision as to 
whether or not to participate in this research study. The person performing the research 
will answer any of your questions. Read the information below and ask any questions you 
might have before deciding whether or not to take part. If you decide to be involved in 
this study, this form will be used to record your consent. 
 
Purpose of the Study 
You have been asked to participate in a research study about the effect of body weight on 
substances that cause constriction (narrowing) of blood vessels. The purpose of this study 
is to determine if the role of these substances if effected by body weight. 
 
What will you to be asked to do? 
Before you can be admitted to the study, you will be given a brief examination during your 
visit to the laboratory. This examination will include filling out a brief health history 
questionnaire, which will include questions about your age, sex, and ethnic origin, as well 
as questions about lifestyle choices (i.e. tobacco use, alcohol consumption etc.). Additional 
measurements will include standard measures of bodyweight, height, blood pressure, and 
heart rate. 
 
If you are eligible for the study you will be enrolled into the study which will be completed 
on the same day. The expected time for you to complete the study day is approximately 4 
hours. Please refer to the following section for a description of the visit to the laboratory. 
 
Laboratory visit – step-by-step protocol 
1. Arrival at laboratory, health history questionnaire 
2. Measures of body height and weight (using a standard scale similar to what is 
used in a doctor’s office). 
3. Measures of blood pressure, heart rate, and skin blood flow, and skin temperature 
during ~3 hrs of resting quietly. 
 Total time in the laboratory: ~ 4 hours 
 
A detailed list of procedures is described below. The potential risks and duration of each 
procedure are provided. If at any time you wish to discuss the information above or any 
 42 
other risks you may experience, you may ask questions now or call the Principal 
Investigators listed on the front page of this form. 
 
Skin blood flow: 
- Description of Procedure: Skin blood flow will be measured at 4 different places 
on your forearm. This measurement will be done using laser-Doppler devices. 
These devices use very low power laser light to measure how fast blood is 
flowing in blood vessels in your skin. Four small probes will be placed on one of 
your forearms. 
- Potential Risks: There are no risks associated with using these devices to 
measure skin blood flow; they are painless and harmless in all respects. 
- Duration of Procedure: Skin blood flow will be measured during the entire 
experiment. 
 
Manipulation of skin temperature: 
- Description of Procedure: Control of local skin temperature is accomplished by 
locally heating the site where skin blood flow is measured. The highest 
temperature we will use is 108° F for 30 minutes. 
- Potential Risks: There are no risks associated with these temperature changes, 
although there is a small risk of minor discomfort at the heated sites. 




- Description of Procedure: Sticky patches will be applied to your skin to measure 
the heart’s electrical signals. 
- Potential Risks: There is no risk or discomfort associated with this procedure. 




- Description of Procedure: Your blood pressure will also be monitored using a 
cuff placed on your upper arm that is inflated and deflated periodically. 
- Potential Risks: Other than some potential discomfort associated with cuff 
inflation there is no risk to this procedure. 
- Duration of Procedure: The cuff will be on your upper arm during the entire 
experiment. We will take blood pressure measurements at different time points 
during the experiment. Each measurement will last approximately 30 seconds. 
 
Placement of Small Microdialysis Tubes: 
- Description of Procedure: These tubes will be used to deliver small amounts of 
commonly used substances into your skin. To do this we will place 4 small 
microdialysis tubes into the skin of one of your forearms. The microdialysis tube 
is placed almost exactly like an "IV" in the hospital, except that veins are not 
entered. First the skin is cleaned with alcohol. Then four very thin (25 gauge) 
needles will be placed just under the surface of your skin on one of your forearms. 
Four special, sterile, thin tubes (about 1/100th of an inch in diameter; about the 
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size of fishing line) with microscopic holes in it will be placed through the needle. 
Then the needle will be removed, leaving the special tubing just under the surface 
of your skin on your forearm. Additional tubing (without holes) will be connected 
to the special tube in your skin and a sterile salt solution that is used in hospitals 
(Ringer’s solution) will be pumped slowly through the tubing assembly. Only a 
tiny amount of the salt solution and drug will go into your skin. After the study 
ends, all tubes are removed. 
- Potential Risks: You may experience some discomfort with the small needles 
used during the placement of the microdialysis tubes. However, after the needles 
have been removed, the microdialysis tubes should not hurt and will be 
physically unnoticeable. 




- Description of Procedure: Throughout the experiment small amounts of 
commonly used drug solutions (see below for description of drug solutions) will 
be delivered through the tubes. These drugs will be used to measure the effect of 
various substances on the constriction (narrowing) of your blood vessels during 
the cold exposure. These drugs will be mixed in a solution called Ringer’s 
solution (similar to a lightly salted solution that is used in hospitals). The drugs to 
be used include L-N
G
-Nitroarginine methyl ester (L-NAME), sodium 
nitroprusside (SNP), Acetylcholine (Ach) and ascorbic acid. 
- Potential Risks: It is possible that there will be some redness of the skin in the 
area where the drug is given. Due to the small concentration of the drugs 
delivered, there is no known risk associated with receiving these drugs. There are 
no known negative experiences in humans with the concentrations of each of the 
drugs. 
- Duration of Procedure: These tubes will be in your forearm during the entire 
experiment. 
 
All tests that are to be performed have safely been used in both healthy and diseased 
individuals. Throughout the tests you will be closely monitored by highly skilled and 
trained personnel. 
 
Because of your participation in this study, you may experience any of the risks cited 
above. You should discuss these with the researchers and your regular health care 
provider. All the tests in this study are designed for research only, not for medical 
purposes. Even though the researchers are not looking at your tests to find or treat a 
medical problem, you will be told if they notice something unusual. You and your regular 
doctor can decide together whether to follow up with more tests or treatment. Because all 
research tests done in this study are not for medical purposes, the research results will not 
be sent to you or to your regular doctor. 
 
This study will last approximately 4 hours, and will take place on a single day. It will 
include approximately 50 study participants. 
This is a research study and, therefore, is not intended to provide a medical or 
therapeutic diagnosis or treatment. The measures and steps taken during the course of 
this study are not necessarily equivalent to the standard method of prevention, diagnosis, 




What are the risks involved in this study?  
All possible risks associated with this study are explained above. The principal 
investigator and laboratory team are experienced with all procedures outlined in this 
study in both healthy and diseased populations. Nevertheless, as with all studies 
involving human subjects, there are risks associated with experimentation that are 
currently unknown. To reduce these risks, you will only be able to join the study if you 
are healthy and you will have to complete a health history questionnaire as a 
precautionary measure to ensure the study poses no additional risks. Furthermore, 
potential risks will also be minimized by: (a) using only safe, well-established 
procedures; (b) constant, personal monitoring of each experimental session by the 
investigators and staff; and (c) knowledge that you can request to stop at any point during 
the procedure. You should immediately tell the research personnel if you are injured or 
harmed in any way during the study. Also, you should know that the principal 
investigator may also terminate the testing procedure at any time. All experimental 
procedures will conform to the University of Texas at Austin Institutional Review Boards 
for Human Subjects. 
 
In addition, the privacy of the subject will be ensured as a result of the record keeping 
process to be employed. All data collected on individual subjects will only be viewed 
by the investigative team involved in the project (i.e., principal investigator, research 
assistant, pre- and postdoctoral research fellows), although these data will be provided 
to the subject. The individual data for each subject will be analyzed and stored by code, 
and at no time will any individual data point be identified with a particular individual 
subject. The data will almost exclusively be presented as average group differences. 
All data and information regarding the study will be kept in the personal, well-secured 
laboratory of the principal investigator. 
 
What are the possible benefits of this study? 
Direct benefits of the study are not guaranteed. The possible benefits of the study are: 1) 
information such as blood pressure readings, heart rate etc. free of charge and 2) 
rewarding contribution to a basis of scientific and clinical knowledge that is likely to 
improve our understanding of blood flow regulation during cold exposure. 
 
Do you have to participate? 
No, your participation is voluntary. You may decide not to participate at all or, if you 
start the study, you may withdraw at any time. Withdrawal or refusing to participate will 
not affect your relationship with The University of Texas at Austin (University) in 
anyway. 
If you would like to participate, you will be asked to fully read and then sign this form. 
The researcher will also sign this form and will provide you with a copy of the signed 
form. 
 
Will there be any compensation? 
You will receive $50.00 upon completion of the entire protocol. If you only participate in 
part of the study day you will receive compensation at a rate of $12.50 per hour spent in 
the lab. Note that in order to process compensation you will be asked to provide your 
social security number. At all times, documents containing social security numbers will 
be stored securely in locked cabinets and in separate files from other study records. 
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Payments will be processed after the study has been completed and this process 
typically takes 3 to 4 weeks. You will be responsible for any taxes assessed on the 
compensation. 
What if you are injured because of the study? 
The University has no program or plan to provide treatment for research related injury or 
payment in the event of a medical problem.  In the event of a research related injury, please 
contact the principal investigator. 
 
What are my confidentiality or privacy protections when participating in this 
research study? 
This study is confidential and your privacy will be ensured as a result of the record 
keeping process to be employed. All data collected on individual subjects will only be 
viewed by the investigative team involved in the project. The individual data for each 
subject will be analyzed and stored by code, and at no time will any individual data point 
be identified with a particular individual subject. All data and information regarding the 
study will be kept in the personal, well-secured laboratory of the principal investigator. 
 
What should you expect if the study is collecting genetic information? 
Genetic information will not be collected in this study. 
 
Whom to contact with questions about the study? 
Prior, during or after your participation you can contact the researcher (R. Matthew 
Brothers, 
PhD) at (512) 232-6016 or send an email to r.m.brothers@austin.utexas.edu. 
 
This study has been reviewed and approved by The University Institutional Review 
Board and the study number is 2013-05-0106. 
 
Whom to contact with questions concerning your rights as a research participant? 
For questions about your rights or any dissatisfaction with any part of this study, you 
can 
contact, anonymously if you wish, the Institutional Review Board by phone at (512) 
471- 8871 or email at orsc@uts.cc.utexas.edu. 
 
Participation 
If you agree to participate in this study, the researcher will accept this form, and provide 






You have been informed about this study’s purpose, procedures, possible benefits and 
risks, and you have received a copy of this form. You have been given the opportunity to ask 
questions before you sign, and you have been told that you can ask other questions at any time. 
You voluntarily agree to participate in this study. By signing this form, you are not waiving any 








As a representative of this study, I have explained the purpose, procedures, benefits, and the 
risks involved in this research study. 
 
 











Research Health Questionnaire 





Today’s Date: ______________  
 
Age ______   Sex  □ Male    





Physician Name and Phone 
Number:_______________________________________________________ 
 
Emergency Contact Info: 
_______________________________________________________________ 
       
Symptoms or Signs Suggestive of Disease 
Check appropriate box:    
Yes No   
□ □ 1. Have you experienced unusual pain or discomfort in your check, neck, jaw, arms 
or other areas that may be due to heart problems? 
□ □ 2. Have you experienced unusual fatigue or shortness of breath at rest, during usual 
activities, or during mild-to-moderate exercise (e.g., climbing stairs, carrying 
groceries, brisk walking, cycling)? 
□ □ 3. When you stand up, or sometimes during the night while you are sleeping, do 
you have difficulty breathing? 
□ □ 4. Do you lose your balance because of dizziness or do you ever lose 
consciousness? 
□ □ 5. Do you suffer from swelling of the ankles (ankle edema)? 
□ □ 6. Have you experienced an unusual and rapid throbbing or fluttering of the heart? 
□ □ 7. Have you experienced severe pain in your leg muscles during walking? 
□ □ 8. Has a doctor told you that you have a heart murmur? 
 
Chronic Disease Risk Factors 
Check appropriate box: 
Yes No   
□ □ 9a. Are you a male over age 45 years or a female over age 55 years? 




□ □  c. If you answered “yes” to 9b, are you on estrogen replacement therapy? 
□ □ 10. Has your father or brother had a heart attack or died suddenly of heart disease 
before the age of 55; has your mother or sister experienced these heart problems 
before the age of 65? 
□ □ 11. Are you a current cigarette smoker? 










□ □ 12. Has a doctor told you that you have high blood pressure (more than 140/90 mm 
Hg) or a heart condition? 
□ □ 13. Is your total serum cholesterol greater than 200 mg/dl, or has a doctor told you 
that your cholesterol is at a high risk-level? 
□ □ 14. Do you have diabetes mellitus? 
□ □ 15. Are you physically inactive and sedentary (little physical activity on the job or 
during leisure time)? 
□ □ 16. Do you have a bone or joint problem that could be made worse by a change in 
your physical activity? 
□ □ 17. During the past year, would you say that you have experienced enough stress, 
strain, and pressure to have a significant effect on your health? 
□ □ 18. Do you eat foods nearly every day that are high in fat and cholesterol such as 
fatty meats, cheese, fried foods, butter, whole milk, or eggs? 
□ □ 19. Do you weigh 30 or more pounds than you should? 
□ □ 20. Do you know of any other reason you should not do physical activity? 
 
Medical History 
21. Please check which of the following conditions you have had or now have.  Also check 
medical conditions in your family (father, mother, brother(s), or sister(s)).  Check as many as 
apply. 
 
Self Family Medical Condition  Self Family Medical Condition 
□ □ Coronary heart disease, heart 
attack; by-pass surgery 
 □ □ Major injury/fracture to 


















□ □ Angina  □ □ Major injury/fracture to 
hip or shoulder □ □ Marfan’s syndrome 
□ □ High blood pressure  □ □ Recent leg trauma/injury 
□ □ Peripheral vascular disease  □ □ Rheumatoid arthritis 
□ □ Phlebitis or emboli  □ □ Osteoarthritis 
□ □ Other heart problems  □ □ Osteoporosis 




□ □ Asthma  □ □ Chronic fatigue syndrome 
□ □ Bronchitis  □ □ Systemic lupus 
erythematosus 
□ □ C.O.P.D. (emphysema)  □ □ Anemia (low iron) 
□ □ Pulmonary embolism 
(blood clots in lungs) 
 □ □ Thyroid problems 
□ □ Gout 
□ □ Deep vein thrombosis 
(blood clots in legs) 
 □ □ Kidney disease 
□ □ Nephrotic (kidney) 
syndrome 
□ □ Antithrombin III deficiency  □ □ Gallstones/gallbladder 
disease 
□ □ Inherited hypercoaguability  □ □ Liver disease (cirrhosis) 
□ □ Acquired hypercoaguability  □ □ Hepatitis 
□ □ Factor V leiden mutations  □ □ Diabetes mellitus 
□ □ Protein C deficiency  □ □ Raynaud’s disease 
□ □ Protein S deficiency  □ □ Crohn’s disease 
□ □ Stomach/duodenal ulcer  □ □ Hysterectomy 
□ □ Rectal growth or bleeding  □ □ Problems with 
menstruation 
 
Self Family Medical Condition  Self Family Medical Condition 
□ □ Irritable bowel syndrome   □ 
□ 




□ □ Lung cancer    Date:  
□ □ Breast cancer  □ □ Allergies 
□ □ Prostate cancer  □ □ Depression 
□ □ Skin cancer  □ □ Anxiety, phobias 
□ □ Colorectal cancer  □ □ Eating disorders  
□ □ Other cancer   
Specify: 
 □ □ Substance abuse problems 
(alcohol, other drugs, etc.) 
□ □ Hearing loss  □ □ Sleeping problems 
□ □ Cataracts  □ □ Other 
□ □ Glaucoma    Specify:  
□ □ Raynaud’s Disease 
 
 
Please specify and include information on any recent illnesses, hospitalizations, surgical 








22a. Are you currently pregnant, think you may be pregnant, or are currently trying to get 
pregnant? 
         □ Yes   □ No            □ Not sure      □ Not applicable (male or post-
menopausal) 
         b. If you answered “yes” or “not sure” to 22a, do you need a pregnancy test?    □ Yes     □ 
No 
 
23.  In the past two weeks, have you had a barium test, a nuclear medicine scan, or x-rays with a 
dye injection?  
        □ Yes   □ No   
 
24. Do you have any adverse reactions to cold water / temperatures?     
□ Yes   □ No         
 
25.  Please check any of the following medications you take regularly and give the name and 
dose of the medication. 
Medication              Name of Medication 
□ Heart medicine    ______________________________________ 
□ Blood pressure medicine   ______________________________________ 
□ Blood cholesterol medicine   ______________________________________ 
□ Thromboembolic disease medicine  ______________________________________ 
□ Hypercoaguability medicine  ______________________________________ 
□ Steroids     ______________________________________ 
□ Hormones/HRT    ______________________________________ 
□ Birth control medicine   ______________________________________ 
□ Medicine for breathing/lungs  ______________________________________ 
□ Insulin     ______________________________________ 
□ Other medicine for diabetes  ______________________________________ 
□ Arthritis medicine    ______________________________________ 
□ Medicine for depression   ______________________________________ 
□ Medicine for anxiety   ______________________________________ 
□ Thyroid medicine    ______________________________________ 
□ Medicine for ulcers    ______________________________________ 
□ Painkiller medicine    ______________________________________ 
□ Allergy medicine    ______________________________________ 
□ Dietary supplements (herbs, vitamins, etc) ______________________________________ 
□ Other (please specify)   ______________________________________ 
 
26.  Do you have any known drug allergies? ______________________________________ 
 
Body Weight 
27. What is the most you have ever weighed? ______________  
28. Are you now trying to: 






29. During the past month, how would you rate your overall level of stress? 
□ Very high  □ High  □ Moderate  □ Low 
 
30. In the past year, how much effect has stress had on your health? 
□ A lot   □ Some  □ Hardly any or none 
 
31. On average, how many hours of sleep do you get in a 24-hour period? 
□ Less than 5  □ 5-6  □ 7-9  □ More than 9 
 
Substance Use 
32. How would you describe your cigarette smoking habits? 
□ Never smoked 
□ Used to smoke.  How many years has it been since you smoked?  _______ years 
□ Still smoke.  How many cigarettes a day do you smoke on average?            cigarettes/day 
 
33. How many alcoholic drinks do you consume? (A “drink” is a glass of wine, a wine cooler, a 
16oz   
       bottle/12oz can of beer, a shot glass of liquor, or a mixed drink). 
□ Never use alcohol  □ Less than 1 per week  □ 1-6 per week  
□ 1 per day              □ 2-3 per day    □ More than 3 per day 
 
34. In one sitting, how many drinks do you typically consume?  ____________________ 
35. How many cups (8 ounces) of coffee do you drink per day? ____________________ 
36. How many ounces of sodas containing caffeine do you drink per day? ____________ 
 
Physical Fitness, Physical Activity/Exercise 
37. Considering a 7-Day period (a week), how many times on the average do you do the 
following kinds of exercise for more than 15 minutes during your free time (write on each 
line the appropriate number). 
 
 
a)  STRENUOUS EXERCISE (HEART BEATS RAPIDLY)             Times Per Week 
    (i.e. running, jogging, hockey, football, soccer, squash, basketball, 
     cross country skiing, judo, roller skating, vigorous swimming,   ______________ 
     vigorous long distance bicycling) 
 
b) MODERATE EXERCISE (NOT EXHAUSTING)   
 (i.e. fast walking, baseball, tennis, easy bicycling, volleyball, 
 badminton, easy swimming, alpine skiing, popular and folk dancing)  _____________ 
 
c) MILD EXERCISE (MINIMAL EFFORT) 
 (i.e. yoga, archery, fishing from river bank, bowling, horseshoes, golf, 
 snow-mobiling, easy walking)       _____________ 
 
38. Considering a 7-Day period (a week), during your leisure-time, how often do you 





   □ OFTEN  □ SOMETIMES   □ NEVER/RARELY 
 
39. How long have you exercised or played sports regularly? 
  □ I do not exercise regularly             □ Less than 1 year        □ 1-2 years 









Research Subject Information 








Subject ID/SSN: __________________________ 
 
 
Date of Birth: ____________  Age: ______   Sex  □ Male    
□ Female 
     
Ethnic Background:         
 
Race: 
      











Emergency Contact Info: _________________________________________________________  
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